Advice - reimburse vibegron (Obgemsa®) for the treatment of an overactive bladder
The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse vibegron (Obgemsa®) from the basic healthcare package. This medicinal product can be used in certain patients with an overactive bladder. If the Minister adopts our advice, zilucoplan will be included in the Medicine Reimbursement System (GVS). Only then will this medicinal product be reimbursed from the health care insurer’s basic health care package.
Vibegron is intended for people with an overactive bladder
Vibegron is the active substance. The brand name is Obgemsa®. The medicinal product is a tablet.
The medicine can be used as a symptomatic treatment in people with overactive bladders. A symptomatic treatment tries to suppress the symptoms of a condition. Overactive means something is either very or too active. In the case of an overactive bladder, this means that the muscles in the bladder sometimes contract suddenly, squeezing urine from of the bladder. People then feel a sudden urge to urinate and sometimes suffer from urine loss at inconvenient times.
Advice from the National Health Care Institute on the reimbursement of vibegron
The National Health Care Institute advises the Minister of VWS to reimburse vibegron (Obgemsa®) from the basic healthcare package. The recommendation is to include the medicinal product in List 1A of the GVS.
For more information on the GVS and the Lists 1A, 1B and 2, see page ‘Reimbursement of extramural drugs (GVS)’.
More information or questions?
If you have any questions about this advice, please send your question to the National Health Care Institute via warcg@zinl.nl. If you have questions about the reimbursement of a medicinal product, the personal expenses or whether you should pay a contribution, please ask your health insurance provider.
How did the advice come about?
The Minister of VWS asks the National Health Care Institute to make an assessment. The Minister makes the final decision whether or not to reimburse the medicinal product from the basic healthcare package.
Explanation about the reimbursement of medicinal products
Vibegron is an extramural medicinal product. Extramural means: medicines for home use that can be obtained at the pharmacy with a prescription from a physician. They are only reimbursed from the basic health care package if they are listed in the GVS.